Michael Kresken

2.2k total citations
73 papers, 1.4k citations indexed

About

Michael Kresken is a scholar working on Pharmacology, Molecular Medicine and Infectious Diseases. According to data from OpenAlex, Michael Kresken has authored 73 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Pharmacology, 35 papers in Molecular Medicine and 32 papers in Infectious Diseases. Recurrent topics in Michael Kresken's work include Antibiotic Resistance in Bacteria (35 papers), Antibiotics Pharmacokinetics and Efficacy (34 papers) and Antimicrobial Resistance in Staphylococcus (26 papers). Michael Kresken is often cited by papers focused on Antibiotic Resistance in Bacteria (35 papers), Antibiotics Pharmacokinetics and Efficacy (34 papers) and Antimicrobial Resistance in Staphylococcus (26 papers). Michael Kresken collaborates with scholars based in Germany, United States and Switzerland. Michael Kresken's co-authors include B. Wiedemann, D. Häfner, Harald Seifert, Barbara Körber-Irrgang, Wolfgang Witte, Christa Cuny, Paul G. Higgins, Ralf René Reinert, Thomas A. Wichelhaus and Christof von Eiff and has published in prestigious journals such as SHILAP Revista de lepidopterología, Clinical Infectious Diseases and Scientific Reports.

In The Last Decade

Michael Kresken

72 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Kresken Germany 21 669 474 448 426 310 73 1.4k
Kim Nichol Canada 19 756 1.1× 674 1.4× 376 0.8× 375 0.9× 207 0.7× 33 1.5k
Iciar Rodríguez-Avial Spain 23 580 0.9× 469 1.0× 435 1.0× 347 0.8× 285 0.9× 66 1.4k
Flávia Rossi Brazil 24 530 0.8× 581 1.2× 469 1.0× 233 0.5× 233 0.8× 92 1.3k
Glen Hansen United States 18 579 0.9× 501 1.1× 297 0.7× 354 0.8× 274 0.9× 32 1.3k
Ronald N. Jones United States 18 675 1.0× 454 1.0× 550 1.2× 415 1.0× 484 1.6× 45 1.5k
Melanie Baxter Canada 24 841 1.3× 679 1.4× 337 0.8× 448 1.1× 320 1.0× 76 1.6k
Marie-Dominique Kitzis France 19 799 1.2× 523 1.1× 411 0.9× 683 1.6× 198 0.6× 48 1.5k
M. Roussel‐Delvallez France 14 606 0.9× 713 1.5× 271 0.6× 311 0.7× 255 0.8× 43 1.6k
M Visalli United States 20 946 1.4× 538 1.1× 292 0.7× 613 1.4× 159 0.5× 32 1.6k
Eugenio A. Debbia Italy 21 541 0.8× 667 1.4× 577 1.3× 312 0.7× 251 0.8× 94 1.6k

Countries citing papers authored by Michael Kresken

Since Specialization
Citations

This map shows the geographic impact of Michael Kresken's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Kresken with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Kresken more than expected).

Fields of papers citing papers by Michael Kresken

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Kresken. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Kresken. The network helps show where Michael Kresken may publish in the future.

Co-authorship network of co-authors of Michael Kresken

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Kresken. A scholar is included among the top collaborators of Michael Kresken based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Kresken. Michael Kresken is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Naber, Kurt G., Flo ri an Wagenlehner, Michael Kresken, et al.. (2023). Escherichia coli resistance, treatment patterns and clinical outcomes among females with uUTI in Germany: a retrospective physician-based chart review study. Scientific Reports. 13(1). 11 indexed citations
3.
Seifert, Harald, et al.. (2023). In Vitro Activity of Cefiderocol against a Global Collection of Carbapenem-Resistant Acinetobacter baumannii Isolates. Antibiotics. 12(7). 1172–1172. 13 indexed citations
4.
Kresken, Michael, Sören Gatermann, Yvonne Pfeifer, et al.. (2023). In Vitro Activity of Cefiderocol against Clinical Gram-Negative Isolates Originating from Germany in 2016/17. Antibiotics. 12(5). 864–864. 2 indexed citations
5.
Kresken, Michael, Paul G. Higgins, Danuta Stefanik, et al.. (2022). The evolution of carbapenem resistance determinants and major epidemiological lineages among carbapenem‐resistant Acinetobacter baumannii isolates in Germany, 2010‐2019. International Journal of Antimicrobial Agents. 60(5-6). 106689–106689. 14 indexed citations
6.
7.
Kresken, Michael, Ingo Klare, Thomas A. Wichelhaus, et al.. (2021). Glycopeptide resistance in Enterococcus spp. and coagulase-negative staphylococci from hospitalised patients in Germany: occurrence, characteristics and dalbavancin susceptibility. Journal of Global Antimicrobial Resistance. 28. 102–107. 12 indexed citations
8.
Kresken, Michael, Sören Gatermann, Yvonne Pfeifer, et al.. (2020). In vitro activity of cefiderocol against aerobic Gram-negative bacterial pathogens from Germany. International Journal of Antimicrobial Agents. 56(4). 106128–106128. 22 indexed citations
9.
Kresken, Michael, Yvonne Pfeifer, & Guido Werner. (2020). Temocillin susceptibility in Enterobacterales with an ESBL/AmpC phenotype. International Journal of Antimicrobial Agents. 57(1). 106223–106223. 8 indexed citations
10.
Brinkmann, Alexander, Anka C. Röhr, Otto Frey, et al.. (2018). S2k-Leitlinie der PEG zur kalkulierten parenteralen Initialtherapie bakterieller Erkrankungen bei Erwachsenen. Der Anaesthesist. 67(12). 936–949. 13 indexed citations
11.
Kresken, Michael, Barbara Körber-Irrgang, Douglas J. Biedenbach, et al.. (2015). Comparative in vitro activity of oral antimicrobial agents against Enterobacteriaceae from patients with community-acquired urinary tract infections in three European countries. Clinical Microbiology and Infection. 22(1). 63.e1–63.e5. 43 indexed citations
12.
Kresken, Michael, et al.. (2014). Antimicrobial susceptibility and molecular epidemiology of Neisseria gonorrhoeae in Germany. International Journal of Medical Microbiology. 304(5-6). 586–591. 16 indexed citations
13.
Körber-Irrgang, Barbara, et al.. (2012). Comparative activity of pradofloxacin and marbofloxacin against coagulase‐positive staphylococci in a pharmacokinetic–pharmacodynamic model based on canine pharmacokinetics. Journal of Veterinary Pharmacology and Therapeutics. 35(6). 571–579. 6 indexed citations
14.
Kresken, Michael. (2008). Effect of pH on the In Vitro Activity of Finafloxacin against Gram-negative and Gram-positive Bacteria. 46th Annual Meeting. 6 indexed citations
15.
Kresken, Michael, et al.. (2005). Surveillance of linezolid resistance in Germany, 2001–2002. Clinical Microbiology and Infection. 11(1). 39–46. 21 indexed citations
16.
Kresken, Michael. (2004). Resistenzsituation bei grampositiven Infektionserregern in Deutschland: Wie wirksam sind Linezolid und Telithromycin?. Pharmazie in unserer Zeit. 33(1). 20–27. 1 indexed citations
17.
18.
Naber, Kurt G., et al.. (1997). Urine bactericidal activity of pefloxacin versus norfloxacin in healthy female volunteers after a single 800-mg oral dose. Infection. 25(2). 121–126. 15 indexed citations
19.
Reinert, Ralf René, Alexander Queck, Achim Kaufhold, Michael Kresken, & Rudolf Lütticken. (1995). Antimicrobial Resistance and Type Distribution of Streptococcus pneumoniae Isolates Causing Systemic Infections in Germany, 1992-1994. Clinical Infectious Diseases. 21(6). 1398–1401. 56 indexed citations
20.
Wiedemann, B., et al.. (1989). The epidemiology of  -lactamases. Journal of Antimicrobial Chemotherapy. 24(suppl B). 1–22. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kim Nichol Breakdown of academic impact, for papers by Iciar Rodríguez-Avial Breakdown of academic impact, for papers by Flávia Rossi Breakdown of academic impact, for papers by Glen Hansen Breakdown of academic impact, for papers by Ronald N. Jones Breakdown of academic impact, for papers by Melanie Baxter Breakdown of academic impact, for papers by Marie-Dominique Kitzis Breakdown of academic impact, for papers by M. Roussel‐Delvallez Breakdown of academic impact, for papers by M Visalli Breakdown of academic impact, for papers by Eugenio A. Debbia
Rankless by CCL
2026